AzTrials
AzTrials

Edentulous Alveolar RidgeNCT06808724

Clinical Influence of Different Surface Treatments on Implant Stabiity

An observational study of Edentulous Alveolar Ridge, run by International Piezosurgery Academy at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to monitor, within a cohort of patients requiring rehabilitation at two different sites in the premolar area, the primary and secondary stability of implants placed with different surface treatments: vacuum-plasma activation, ozonated oil and non-activated implants. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Edentulous Alveolar Ridge
What is being tested?
implant with ozonated oil, non-activated implant and implant with plasma activation
Type of treatment
Surgery or procedure
How many people
32 participants
Where
1 siteItaly
Study dates
31 Jan 2025to 31 Dec 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: After investigating general and local anamnesis, which included evaluation of systemic illnesses and potential allergies, a dental visit was conducted to formulate a specific treatment plan. If the patient was deemed eligible for the research protocol, an additional periapical radiograph was obtained for each selected site to assess the adequacy of residual bone height. If the available bone height appeared to be sufficient, a second-level radiographic exam, a Cone Beam Computed Tomography (CBCT), was performed to evaluate whether the bone volume was adequate for supporting implant rehabilitation. For patients requiring tooth extraction, this second assessment was performed after six months of healing after extraction.

Who may be able to join

  • Age older than 18 years old;
  • Indication for an implant-supported rehabilitation in the left and right upper premolar/first molar areas;
  • The area in which the implants will be placed must have had at least 6 months of healing;
  • No use of grafts or bone substitutes following tooth extraction;
  • Bone volume measuring at least 10 mm in height and 6 mm in width;
  • Absence or decision to not wear a removable prosthesis during the healing period;
  • Patients with good and stable oral hygiene;
  • Signed informed consent form.

Who cannot join

  • Acute myocardial infarction within the previous six months;
  • Uncontrolled bleeding disorders;
  • Uncontrolled diabetes (HBA1c > 7.5%);
  • Radiotherapy in the head-neck area in the previous 48 months;
  • Immunocompromised patients (es. AIDS / chemotherapy);
  • Current or previous treatment with antiresorptive drugs via intravenous injection;
Show all 12Show fewer
  • Psychological or psychiatric disease;
  • Alcohol and /or drugs abuse;
  • Heavy smokers (more than 10 cigarettes / day);
  • Plaque index >20% and/or bleeding on probing >10%
  • Pregnant or breastfeeding patients;
  • Patients refusing to participate in follow-up checks.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Claudio Stacchi, Dott. contact

+39 0403992254

claudio@stacchi.it

Italy1 site, 1 recruiting
  • University of Trieste

    Trieste, TS, 34125

    Claudio Stacchi, DDS, MSc, +39 0403992254, claudio@stacchi.it

    Recruiting

Other trials in Italy

About this study

Official title: Clinical Influence of Different Surface Treatments on Implant Stabiity: a Prospective Observational Clinical Study

The goal of this observational study is to monitor, within a cohort of patients requiring rehabilitation at two different sites in the premolar area, the primary and secondary stability of implants placed with different surface treatments: vacuum-plasma activation, ozonated oil and non-activated implants.

Read the detailed description

The primary outcome measures included primary implant stability, assessed through insertion torque and the Implant Stability Quotient (ISQ).

Secondary outcome measures included the pattern of implant secondary stability during the first 90 days post-implant placement (ISQ), implant survival after one year, NPRS comparison between treatments at one week postoperatively, and any complications or adverse events.

As an additional objective, the study aimed to assess whether a relationship existed between implant surface treatment and early marginal bone loss. Marginal bone levels were measured at three time points: immediately after surgery (T0), upon delivery of prosthetic rehabilitation (T1), and after one year of loading (T2). The distance between the implant platform and the bone crest was measured at each interval, on both the mesial and distal aspects of the implant. A positive value was assigned when the bone crest was coronal to the implant platform, whereas a negative value was assigned when the bone crest was apical to the implant platform.

Study Design: Observational, prospective, non-profit case-control study.

Study Population: The study will be conducted in an outpatient hospital setting.

Enrollment Procedure: All patients meeting the inclusion and exclusion criteria will be enrolled in the study after receiving the Information Sheet and providing written informed consent.

Patients seeking implant-supported rehabilitation due to the absence of at least two teeth were initially evaluated with a periapical radiograph of the selected sites to assess residual bone height adequacy. If sufficient bone height was observed, a second-level radiographic examination using Cone Beam Computed Tomography (CBCT) was performed to confirm the adequacy of bone volume for implant rehabilitation.

Surgical Phase: Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap was elevated. The same surgeon performed all procedures. Implant site preparation was performed using twist drills. In one group, ozonated oil (Surgy O3, Biosanity) was applied to the implant surface and then the implant was inserted into the prepared osteotomy site. A transepithelial abutment was then attached using a torque wrench, tightened to 30 Ncm. In the second group, implant underwent vacuum-plasma activation immediately before insertion (Plasma X Motion, Megagen, Gyeongbuk, South Korea) and then it was inserted into the prepared osteotomy site. A transepithelial abutment was then attached using a torque wrench, tightened to 30 Ncm. In the control group, the implant was inserted without any treatment. A transepithelial abutment was then attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures were used to close the flaps.

A postoperative radiographic assessment was conducted to verify correct implant positioning.

A blinded operator measured ISQ values for each implant in two directions: vestibular-palatal and mesio-distal. Measurements were taken at the abutment level three times per direction, and the averages were used for statistical analysis.

ISQ measurements were performed using a Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden).

Follow-up: After surgery, a follow-up visit was scheduled after one week for suture removal, soft tissue healing assessment, and ISQ measurements. Additional follow-ups occurred at 14, 21, 28, 42, 56, and 90 days, with the same parameters reassessed at each visit.

All implants were restored with screw-retained single metal-ceramic crowns four months after surgery and were followed up for at least 12 months after prosthetic loading. Radiographic check-ups were conducted at 6 months and 1 year.

For the sample size calculation, it was assumed that the minimal clinically relevant difference between the groups was 5 points on the ISQ scale, with a standard deviation of 5. Using an 80% power and a 95% significance level, the calculation yielded a sample size of approximately 16 participants per group (rounded to the next whole number). This ensures sufficient power to detect the anticipated difference between the groups.

Statistical Plan: Statistical analysis will be performed using a computerized statistical package (SigmaStat 3.5, SPSS Inc., Germany). Data will be expressed as mean ± standard deviation or median (interquartile range) for parametric and non-parametric values, respectively.

Being tested
implant with ozonated oil, non-activated implant, implant with plasma activation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • implant with ozonated oilProcedure or surgery

    Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Ozonated oil (Surgy O3) will be applied to the implant surface and then the implant will be inserted into the prepared osteotomy site. A 3 mm high transepithelial abutment will be then screwed using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.

  • non-activated implantProcedure or surgery

    Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. In the control group, the implant will be inserted without any treatment. A 3 mm high transepithelial abutment will be then attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.

  • implant with plasma activationProcedure or surgery

    Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Implant will undergo vacuum-plasma activation immediately before insertion (Plasma X Motion, Megagen, Gyeongbuk, South Korea) and then it will be inserted into the prepared osteotomy site. A transepithelial abutment will then be attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.

Study groups in NCT06808724
Study groupRoleWhat they receive
Testozonated oil / plasma activation
Receives: Procedure: implant with ozonated oil; Procedure: implant with plasma activation
ControlNo surface treatment
Receives: Procedure: non-activated implant

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Implant primary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: Immediately after implant placement

  2. Implant primary stability in Newton

    Insertion torque

    Measured: Immediately after implant placement

Secondary outcomes (7)
  1. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 7 days after implant insertion

  2. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 14 days after implant insertion

  3. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 21 days after implant insertion

  4. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 28 days after implant insertion

  5. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 42 days after implant insertion

  6. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 56 days after implant insertion

  7. Implant secondary stability measured with RFA device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden)

    Measured: 90 days after implant insertion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2025
  2. Study start31 Jan 2025
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06808724
Sponsor's protocol ID
IMPLANT SURFACE MODIFICATIONS
Status last verified
Jan 2025
First submitted
21 Jan 2025
Last updated
5 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Edentulous Alveolar Ridge, run by International Piezosurgery Academy at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Claudio Stacchi, Dott. (+39 0403992254, claudio@stacchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Implant primary stability measured with RFA device (Osstell) (time frame: Immediately after implant placement). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in